{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:17:06Z","timestamp":1777479426873,"version":"3.51.4"},"reference-count":128,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Grifols, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Antithrombin (AT), a glycoprotein, plays a key role in anticoagulation by inhibiting coagulation proteases. It is also the primary mediator of heparin's anticoagulant effect, with heparin binding amplifying AT activity up to 1000-fold. Deficiency in AT contributes to a hypercoagulable state associated with adverse clinical outcomes, including morbidity and mortality. Hereditary AT deficiency (hATD) is a rare autosomal dominant disorder caused by mutations in the gene encoding AT (\n                    <jats:italic toggle=\"yes\">SERPINC1<\/jats:italic>\n                    ), resulting in decreased AT levels or activity. As the most thrombogenic inherited thrombophilia, hATD confers a lifetime venous thromboembolism (VTE) risk of up to 85%, with similar annual VTE incidence in both pediatric and adult patients. Management of hATD often includes AT concentrate (ATc) therapy in high-risk clinical settings. Although ATc has a long history of use in adults, pediatric use has been largely off-label and guided by extrapolation from adult data. In August 2025, the U.S. Food and Drug Administration (FDA) approved an expanded indication for antithrombin III concentrate (human) to include pediatric patients with hATD, representing the first product specifically approved for this population. In light of this recent shift in the treatment landscape, this review provides a timely synthesis of the current clinical understanding and evidence-informed strategies to optimize AT therapy in the management of pediatric hATD.\n                  <\/jats:p>","DOI":"10.1177\/10760296261425036","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:56:44Z","timestamp":1771437404000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary Antithrombin Deficiency in Pediatric Patients: Pathophysiology, Clinical Features, Diagnosis, and Antithrombin Replacement Therapy"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1234-0128","authenticated-orcid":false,"given":"George M.","family":"Rodgers","sequence":"first","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilton I.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"SSNA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.878199"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5049.144643"},{"key":"e_1_3_3_4_2","first-page":"2076","volume-title":"Hematology (Seventh Edition)","author":"Anderson JA","year":"2018","unstructured":"Anderson JA, Hogg KE, Weitz JI, et al. Chapter 140 \u2013 hypercoagulable states. In: Hoffman R, Benz EJ, Silberstein LE, eds. Hematology (Seventh Edition). Elsevier; 2018:2076-2087."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.15371"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00443-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767100-00005"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9261351"},{"key":"e_1_3_3_9_2","unstructured":"Thrombate III prescribing information [Internet]. Grifols\/Talecris. 1991; https:\/\/www.thrombate.com\/en\/home. Accessed September 9 2024."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.5.320"},{"issue":"12","key":"e_1_3_3_11_2","first-page":"764","article-title":"Antithrombin III utilization in a large teaching hospital","volume":"38","author":"Salas CM","year":"2013","unstructured":"Salas CM, Miyares MA. Antithrombin III utilization in a large teaching hospital. P T. 2013;38(12):764-779.","journal-title":"P T"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.06.036"},{"key":"e_1_3_3_13_2","volume-title":"August 21, 2025 approval letter: Pediatric Use in the Prescribing Information label for THROMBATE III\u00ae [antithrombin III (human)]","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. August 21, 2025 approval letter: Pediatric Use in the Prescribing Information label for THROMBATE III\u00ae [antithrombin III (human)]. Center for Biologics Evaluation and Research, U.S. Food and Drug Administration; 2025."},{"key":"e_1_3_3_14_2","unstructured":"Grifols Therapeutics LLC. THROMBATE III [antithrombin III (human)] \u2013 Full Prescribing Information (Revised July 2025). 2025."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387464"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2021.100094"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01830.x"},{"key":"e_1_3_3_18_2","volume-title":"StatPearls [Internet].","author":"Hsu E","year":"2024","unstructured":"Hsu E, Moosavi L. Biochemistry, Antithrombin III. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14648"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-08-0687"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231205279"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2009.12.001"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4449"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102552"},{"key":"e_1_3_3_25_2","unstructured":"ARUP Laboratories. Antithrombin Panel. ARUP Laboratories Test Directory 2025; https:\/\/ltd.aruplab.com\/Tests\/Pub\/0030370. Accessed 15 Oct 2025."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.1.165.165"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.1998.1998"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04905.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1975.tb03893.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.008"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-01-0047"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1046646"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000216099"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.900.900"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e328350294a"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-12-0964"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365516509077290"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2726-9"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-08-0635"},{"issue":"2","key":"e_1_3_3_40_2","first-page":"130","article-title":"Deficiencies of the natural anticoagulants \u2013 novel clinical laboratory aspects of thrombophilia testing","volume":"27","author":"Bereczky Z","year":"2016","unstructured":"Bereczky Z, Gindele R, Speker M, Kallai J. Deficiencies of the natural anticoagulants \u2013 novel clinical laboratory aspects of thrombophilia testing. EJIFCC. 2016;27(2):130-146.","journal-title":"EJIFCC"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03142.x"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-025-00801-0"},{"key":"e_1_3_3_43_2","doi-asserted-by":"crossref","unstructured":"The Human Gene Mutation Database SERPINC1 gene. 2023; https:\/\/www.hgmd.cf.ac.uk\/ac\/gene.php?gene=SERPINC1. Accessed Jan 5 2026.","DOI":"10.1155\/2023\/8872346"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04878.x"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830450409"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1841-0399"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002927"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.16.6.742"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01197.x"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04858.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-05-0402"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-406207"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.01.037"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.210666"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13252"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-019-03433-5"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.07.008"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/mas.21929"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.913673"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.19.4.1026"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-2-200301210-00014"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2353"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.02.029"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.07.026"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03840.x"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.06.004"},{"issue":"11","key":"e_1_3_3_67_2","first-page":"3702","article-title":"The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study","volume":"94","author":"Sanson BJ","year":"1999","unstructured":"Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood. 1999;94(11):3702-3706.","journal-title":"Blood"},{"issue":"5","key":"e_1_3_3_68_2","first-page":"695","article-title":"The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S","volume":"91","author":"De Stefano V","year":"2006","unstructured":"De Stefano V, Simioni P, Rossi E, et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica. 2006;91(5):695-698.","journal-title":"Haematologica"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614442"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405514"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002781"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.211433"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.789008"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-02-0149"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016651276"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-0792-8.00057-X"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21893"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1160\/Th14-05-0446"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04584.x"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12372"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.228"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X15575769"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1197-3"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.11.011"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13342"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.5858\/2002-126-1326-AD"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3680"},{"key":"e_1_3_3_88_2","unstructured":"National Center for Biotechnology Information (NCBI). Antithrombin III deficiency. 2025; https:\/\/www.ncbi.nlm.nih.gov\/gtr\/tests\/249713\/. Accessed January 5 2026."},{"key":"e_1_3_3_89_2","unstructured":"National Center for Biotechnology Information (NCBI). SERPINC1 Gene Full Gene NGS. 2025; https:\/\/www.ncbi.nlm.nih.gov\/gtr\/tests\/614880\/. Accessed January 5 2026."},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100079"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010177"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2019-0026"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1297170"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2017.00050"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009514"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000809"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.02.136"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2486-6735"},{"key":"e_1_3_3_99_2","unstructured":"Atryn prescribing information [Internet]. GTC Biotherapeutics Inc. 2009; https:\/\/www.fda.gov\/media\/75529\/download?attachment. Accessed September 9 2024."},{"key":"e_1_3_3_100_2","unstructured":"European Medicines Agency. ATryn Withdrawal of the marketing authorisation in the European Union. 2019; https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-atryn-withdrawal-marketing-authorisation-european-union_en.pdf. Accessed November 14 2024."},{"key":"e_1_3_3_101_2","unstructured":"US Food and Drug Administration. National drug code directory. 2024; https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/national-drug-code-directory. Accessed July 28 2025."},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivt327"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2020.07.006"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc8205"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04972.x"},{"key":"e_1_3_3_106_2","volume-title":"StatPearls [Internet]","author":"Khawar H","year":"2024","unstructured":"Khawar H, Kelley W, Stevens JB, Guzman N.Fresh Frozen Plasma (FFP). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.4103\/ija.ija_1043_22"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-11002-0039"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/78.2.220"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000463"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.2450\/2009.0005-09"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-10-0672"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00315.x"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.1.33.33"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)80533-9"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024786"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2012.02451.x"},{"key":"e_1_3_3_118_2","unstructured":"US Food and Drug Administration. FDA Adverse Events Reporting System (FAERS): Thrombate III 1994-2024. https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/45beeb74-30ab-46be-8267-5756582633b4\/state\/analysis. Accessed October 10 2024."},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102336"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.06.006"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH02-11-0283"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13359"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000174"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194175"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.828702"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11042"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(00)00017-5"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1159\/000244469"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010290108744"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261425036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296261425036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261425036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:41Z","timestamp":1777385141000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296261425036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":128,"alternative-id":["10.1177\/10760296261425036"],"URL":"https:\/\/doi.org\/10.1177\/10760296261425036","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"10760296261425036"}}